news
Spanish Gene Therapy for Alzheimer's Enters Human Trials in Australia
Tetraneuron, a Spanish biotech, received approval to start human trials in Australia for TET-101, a gene therapy targeting moderate Alzheimer's. The company also secured over €4.3 million in public funding. This moves a new mechanism against neurodegeneration closer to patients.
Tetraneuron, a Spanish biotech, received approval to start human trials in Australia for TET-101, a gene therapy targeting moderate Alzheimer's. The company also secured over €4.3 million in public funding. This moves a new mechanism against neurodegeneration closer to patients.
The architecture take
A Spanish biotech just got the green light for human trials of a gene therapy for Alzheimer's in Australia. This isn't about clearing amyloid plaques, which has been the dominant (and largely failed) approach for years. Instead, TET-101 aims to boost brain neurotrophic factors, specifically NGF, to protect neurons directly. Think of it as supplying the brain with more of its own built-in repair crew. The catch with gene therapy is always delivery and off-target effects, but if this works, it could genuinely change the conversation around slowing neurodegeneration. I'm watching this for the mechanism, not just the Alzheimer's angle; new ways to support brain health will eventually spill over into general longevity. Funding from Spain's Ministry of Science is a quiet signal of national investment in biotech solutions beyond Big Pharma's usual suspects.